Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Betamethasone timing during late pregnancy does not affect neonatal outcomes

Tristan Manalac
27 Feb 2020
Postpartum depression: how nurses can help

The timing of betamethasone (BMZ) administration in pregnant women does not seem to differentially affect the suppression of the hypothalamic-pituitary-adrenal (HPA) axis and, in turn, has no apparent effect on neonatal outcomes, according to a study presented at recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).

Researchers enrolled 1,414 eligible women who were then categorized into three according to the time of BMZ administration: epoch 1 (00:00–07:59; n=131; maternal age, 27.3±6.0 years), epoch 2 (08:00–15.59; n=785; maternal age, 28.7±6.1 years) and epoch 3 (16:00–23.59; n=498; maternal age, 28.9±6.0 years). The primary study outcome was a composite of respiratory morbidities.

In terms of baseline characteristics, researchers found a significant between-group difference in terms of having had a previous live-born child with respiratory problems at birth (p=0.011). In particular, this outcome was more common in the epoch 2 vs 1 and 3 (16.6 percent vs 10.7 percent vs 11.0 percent; p=0.011). The remaining baseline factors were comparable across epochs. [SMFM 2020, abstract P637]

Similarly, the rate of caesarean deliveries differed across epochs (p=0.016) and was most common in epoch 3, followed by epochs 2 and 1 (33.1 percent vs 32.7 percent and 20.6 percent). Other pregnancy outcomes, such as gestational age at delivery (p=0.859), sex of infant (p=0.904) and birth weight (p=0.171), were unaffected by the timing of BMZ administration.

Neonatal outcomes were likewise unaffected by BMZ timing. For instance, the primary outcome of composite respiratory morbidities occurred with comparable frequencies in epochs 1, 2 and 3 (11.5 percent vs 12.0 percent vs 10.8 percent; p=0.826).

The prevalence of severe and major respiratory morbidities was set as a secondary outcome and was likewise comparable across epochs (9.2 percent vs 7.7 percent vs 7.6 percent; p=0.839). The composite of neonatal adverse outcomes occurred more commonly but showed a similarly null cross-epoch pattern (36.6 percent vs 32.0 percent vs 36.6 percent; p=0.194).

These findings were confirmed through multivariate logistic regression analysis. Setting epoch 1 as the reference, the likelihood of developing composite respiratory morbidities was insignificant in epoch 2 (odds ratio [OR], 0.97, 95 percent confidence interval [CI], 0.53–1.8) and epoch 3 (OR, 0.93, 95 percent CI, 0.49–1.77).

The same was true for severe respiratory morbidities (epoch 2: OR, 0.82, 95 percent CI, 0.41–1.64; epoch 3: OR, 0.87, 95 percent CI, 0.42–1.79) and adverse outcomes (epoch 2: OR, 0.77, 95 percent CI, 0.51–1.16; epoch 3: OR, 0.98, 95 percent CI, 0.64–1.50).

“In adults, administration of exogenous steroids overnight results in greater HPA axis suppression than when given during the day. This finding has not been shown in pregnancy and the consequent effect on neonatal outcomes is not known,” said the researchers.

The present study was a secondary analysis of a multicentre randomized trial of late preterm BMZ, including women who were at least 34 weeks pregnant at enrolment. Timing of BMZ administration was approximated according to the time of randomization.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).